Welcome to Your AVEO Orientation

2012

CONFIDENTIAL

1

Orientation Schedule – Day 1

Time Topic Facilitator

9:00 AM Breakfast and AVEO Overview Senior Management

9:45 AM AVEO Day-to-Day Resources Tracey Janesheski, HR Associate

10:00 AM Keeping the Workplace Safe Safety

10:15 AM Your AVEO Benefits & EE Photo Jaimie Mailander, HR Associate

12:00 PM Lunch Hiring Manager

2nd Day

9:30 AMQuality Assurance Orientation

Within 1st 60 DaysCheck-In with Your HR Business Partner

Within 1st 60 Days Legal Orientation Joe Vittiglio, Senior VP & General Counsel

27/17/2013 2 CONFIDENTIAL

Who We Are

37/17/2013 3 CONFIDENTIAL

4

The AVEO Executive Committee

From top left corner: Tuan Ha-Ngoc, Jeno Gyuris, Murray Robinson, David Johnston.

Seated, from left: Elan Ezickson, Michael Bailey, Nell Jones, Joseph Vittiglio, Bill Slichenmyer

7/17/2013 4 CONFIDENTIAL

Tuan Ha-NgocPresident/CEO

Joseph VittiglioSr. VP & General

Counsel

-Intellectual Property

Nell JonesSr. VP, Human

Resources

Elan EzicksonExecutive VP &

COO

-Medical Affairs-Technical Operations-Program & Alliance

Management

Michael BaileyChief Commercial

Officer

Commercial & Marketing

Jeno GyurisCSO

-Translational Research-Preclinical

Development-Bioinformatics

David JohnstonCFO

-Finance-Investor Relations

-Facilities-IT

Bill SlichenmyerCMO

-Clinical-Pharmacovigilance

-Biometrics-Regulatory Affairs

Carole Varanelli VP Quality

Rob KloppenbergVP, Corp. Comm. & Public Affairs

The AVEO Organization

CLINICAL ACTIVITIES AND PIPELINE DEALS

HRP AND HRP DEALS

MERGER OF HRP & PRODUCTS/CLINICAL PROGRAMS

SERIES A SERIES B SERIES C SERIES D SUCCESSFUL IPO PIPE FOLLOW-ON

TIVOZANIB PH 2 RCC STUDY INITIATED

FICLATUZUMAB PH 1 INITIATED

AVEO REGAINSRIGHTS TO

FICLATUZUMAB

TIVO-1INITIATED FICLATUZUMAB

PH 2 NSCLC INITIATED

BATON-RCC

BATON-CRC

2002-2012: A Decade of Delivery

2002 | | | | | 2012 6

Human Response Platform™: Insights into Cancer Biology

7/17/2013 CONFIDENTIAL7

U.S. Patent No. 6,639,121 Issued in 2003

Discovery and

validation of

functionally relevant

targets

Maturing pipeline of

novel functional

antibodies

Biomarker-driven identification of responsive patient populations

Genetic signatures of tumors informs rational choice of drug combinations

Biomarker data provides

opportunity to optimize

benefits in selected patients

Supports pricing and

reimbursement

Building A Sustainable Pipeline

7/17/2013 CONFIDENTIAL8

= FOUNDATION FOR BIOMARKER CLINICAL STATEGIES

*Aveo and Astellas Pharma Inc. have a worldwide agreement to co-develop and commercialize tivozanib outside of Asia

**Anti-ErbB3 program is strategically partnered with Biogen Idec

7/17/2013 CONFIDENTIAL9

TIVOZANIB

Potent, Selective and

Long Half-Life Inhibitor

of All Three VEGF

Receptors

RCC market valued at $2B WW1

Despite advances, unmet medical need persists2

Tivozanib: Potential Standard of Care in First-Line RCC

• Current therapies provide less than

12 months of first-line PFS and

therefore there remains a significant

unmet need2

• Reducing the dosage or delaying

treatment of therapies due to AEs

(fatigue, diarrhea and hand-foot

syndrome) is a major limitation2

• Many patients cannot tolerate

current therapies for a long period of

time, impacting potential to achieve

maximal efficacy2

7/17/2013 CONFIDENTIAL101. Wolters Kluwer and IMS Health

2. Campbell Alliance interviews with 7 KOLs. Aug, 8 through Aug. 12, 2011.

Improved EfficacyImproved Safety

and Tolerability

7/17/2013 CONFIDENTIAL

TIVO-1 Top-Line: Statistically Significant Superiority

• Well-tolerated safety profile consistent with Phase 2– Hypertension was most common side effect; on-target class effect and

manageable

– Phase 2 experience:

• Low rate of dose reductions and interruptions, and serious side effects (grade 3/4)

• Hypertension and dysphonia most commonly reported side effects; both mechanism-related, manageable and reversible

• Side effects commonly associated with other VEGFR inhibitors (diarrhea, fatigue and hand-foot syndrome) were notably low

11

SAFETY

EFFICACY

Median PFS / Treatment Naïve (70% of overall)

Tivozanib 12.7 months

Sorafenib 9.1 months

Median PFS / Overall Study

Tivozanib 11.9 months

Sorafenib 9.1 months

Our Total Approach to Patient

7/17/2013 CONFIDENTIAL12

AccessDisease Management

AdvocacySupport

Predictive

Biomarkers

Efficacy Tolerability

Partnership with Astellas

• In February 2011, AVEO and Astellas entered into a worldwide

agreement outside of Asia to develop and commercialize tivozanib

for the treatment of a broad range of cancers.

Astellas, located in Tokyo, Japan, is a pharmaceutical company

with approximately 16,800 employees worldwide

• AVEO will be responsible for the manufacturing of tivozanib and

lead commercialization in North America

• Astellas will lead commercialization in the European Union

• AVEO and Astellas plan to jointly conduct and fund the expansion

of tivozanib clinical development into additional solid tumor types.

CONFIDENTIAL137/17/2013

Where We are Today

• 220+ employees

• US and EU field presence (Germany, UK, France)

14

Cambridge, MA

7/17/2013 14 CONFIDENTIAL

Windsor, UK

AVEO Clinical Trial Sites and MSL Locations

CONFIDENTIAL157/17/2013

RCC KOL Location

CCC Location

Current MSL

Location

16

Future AVEO Headquarters:650 East Kendall

7/17/2013 16

Your AVEO Day-to-Day Resources

7/17/2013 CONFIDENTIAL17

New Hire Resources on the AVEO Insider

18http://aveo/metadot/index.pl?id=3139&isa=Category&op=show7/17/2013 18 CONFIDENTIAL

7/17/2013 CONFIDENTIAL19

AVEO Policies

• AVEO employees are required to read and acknowledge receipt

of the following Company policies– Non-Discrimination & Non-Harassment

– Time Away From Work

– Electronic Communications & Info Systems

– Family & Medical Leave Act

– Laboratory Notebook Policy

– Insider Trading

– Disclosure Policy

– Written Comprehensive Information Security Program (WISP)

• May be required if as part of your position you have access to certain sensitive information

– Overtime and Holiday Policy

• Required only if you are an hourly, or non-exempt, employee

JULY 17, 2013 CONFIDENTIAL19

Staying Informed, Getting Involved

• Quarterly All-Company Meetings

• Annual Summer Outing

• Annual Post-Holiday Celebration

• Various charitable events

20©2012 Vertex Pharmaceuticals Incorporated7/17/2013 20 CONFIDENTIAL

2012 Summer Events : 10th Anniversary Year

7/17/2013 CONFIDENTIAL21

• Celebration at Fenway Park

• Guided tour, dinner, AVEO apparel

• Prouty Ride to benefit the Norris Cotton

Cancer Center

• Second Quarter all company meeting &

poster session

• Day of Community Service

• Corporate Donation of $10,000 in the

name of all employees to the Jimmy

FundJULY 17, 2013 CONFIDENTIAL21

The AVEO Way: Putting the Patient First

7/17/2013 22 CONFIDENTIAL

AVEO Oncology is…

…passionate in our pursuit of improving the lives of cancer patients…

…powered by innovation…

…supportive of a creative and collaborative culture…

…committed to creating value for our shareholders.

This is the AVEO Way – the Human Response.

AVEO Rewards and Recognition Program

• Annual CEO Award - $5,000

• Executive Team Award - $500

• Team Award - $150 AmEx Gift Card

• Spot Award (Individual) - $150 AmEx Gift Card

• Thanks Award - $25 AmEx Gift Card

AVEO’s CEO AwardRecipients:2012 – Andrew Strahs, Sr. Director, Biometrics

7/17/2013 23 CONFIDENTIAL

Connect with Your AVEO Ambassador

• Ambassadors are employees at all levels who:– Know the culture – Know how to get things done – Convey practical knowledge

• Your Ambassador will help you navigate our campus and culture for the first 30 days

247/17/2013 24 CONFIDENTIAL

AVEO Employee Referral Program

257/17/2013 25 CONFIDENTIAL

26

Current AVEO Campus Map

7/17/2013 26 CONFIDENTIAL

27

Future AVEO Headquarters:650 East Kendall

7/17/2013 27